Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | LTA4H | P09960 | 2/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | HRH2 | P25021 | 1/20 | 0.58 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | DRD3 | P35462 | 6/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | DRD2 | P14416 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23301248 | 0.85 | KCNA5 (0.58) | KCNA5LTA4HDRD3KDM4EDRD2 | |
| SCHEMBL19462784 | 0.85 | DRD3 (0.79) | KCNA5DRD3DRD2 | |
| SCHEMBL3972559 | 0.85 | KCNA5 (0.64) | KCNA5LTA4HHRH2HRH1DRD3 | |
| SCHEMBL5480208 | 0.85 | KCNA5 (0.74) | KCNA5LTA4HPTGS2HRH2HRH1 | |
| SCHEMBL2233062 | 0.81 | HRH3 (0.56) | RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL6034847 | 0.81 | HRH2 (0.61) | KCNA5RAB9ALTA4HPTGS2HRH2 | |
| SCHEMBL23303045 | 0.81 | HRH2 (0.60) | KCNA5RAB9ALTA4HHRH2HRH1 | |
| SCHEMBL16795305 | 0.81 | HRH3 (0.72) | LTA4HKDM4E | |
| SCHEMBL14204558 | 0.81 | LTA4H (0.62) | KCNA5LTA4HPTGS2DRD3KDM4E | |
| SCHEMBL26690637 | 0.81 | HTR1B (0.48) | KCNA5RAB9ALTA4HHRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | claimed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | claimed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | claimed |
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | ASTRAZENECA (SE) | 2006-03-09 | — | — | US | disclosed |
| EP-1414801-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | AstraZeneca AB (SE) | 2004-05-06 | — | — | EP | disclosed |
| WO-2003004472-A1 | ARYLAMINES FOR THE TREATMENT OF CONDITIONS ASSOCIATED WITH GSK-3 | ASTRAZENECA AB (SE) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052396-A1 | Arylamines for the treatment of conditions associated with gsk-3 | GSK3A, GSK3B, PYGL | KCNA5 1588/4885RAB9A 859/4885LTA4H 3363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.